Mantle cell lymphoma

Researchers are testing a combination of three drugs, obinutuzumab, ibrutinib, and GDC-0199, in people with mantle cell lymphoma. The trial includes patients whose cancer has come back or stopped responding to treatment, as well as those who have not yet received treatment. The g…

This study looks at how well different immunochemotherapy combinations, such as RCHOP, BR, and RCVP, work for people with small B-cell non-Hodgkin lymphoma. Researchers will track 206 adults with this type of lymphoma to see how many respond to treatment and how long they stay fr…

This Phase 2 trial tests whether adding venetoclax to ibrutinib can improve complete responses in Japanese adults with mantle cell lymphoma that has returned or not responded to treatment. Participants take both oral drugs for about 104 weeks, then continue ibrutinib alone until …

This phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune ce…

This phase I trial is testing a combination of drugs—avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy—in people with diffuse large B-cell lymphoma or mantle cell lymphoma that has returned or not responded to treatment. The goal is to find the safest dose and see how …

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This early-stage study tests an experimental pill called LOXO-338 in 316 adults with advanced blood cancers like leukemia, lymphoma, or multiple myeloma. Participants have already tried standard treatments. The main goals are to find the safest dose and see if the drug shrinks tu…

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …

This phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…

This study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…

This study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…

This study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…

This phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and r…

This study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free …

This study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…

This early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment p…

This early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) as a first treatment for people with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely improve remission rates before a stem cell tran…

This phase 3 trial tested whether adding the targeted drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma, a rare blood cancer. Only 3 patients took part, and the study is now complete. Researche…

This phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many…

This study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…

This study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and …

This phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…

This early-phase study tested a new treatment called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The goal was to find a safe dose and see if the therapy can shrink tumors. The study is now compl…

This early-phase study tested a new cell therapy called C-CAR039 in 3 adults with B-cell non-Hodgkin's lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and CD20) on cancer cells. T…

This study tested a drug called vorinostat in 56 people with certain types of lymphoma (follicular, other indolent B-cell, or mantle cell) that had returned or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared (respon…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had bad side effects from similar drugs like ibrutinib or acalabrutinib. The main goal was to see if zanubrutinib causes…

This study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

This phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, …

This study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that came back or didn't respond to treatment. The goal was to see if this schedule is practical and reduces side effects before patients receive CAR T-cell therapy. The approac…

This study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…

This study tested whether adding the targeted drug venetoclax to standard chemotherapy (R-BAC) helps older patients with high-risk mantle cell lymphoma. 141 patients received the combination, aiming to improve how long they stay cancer-free. The approach is designed for those who…

This early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…

This study tested a drug called zanubrutinib in 55 Japanese patients with B-cell blood cancers that had come back or not responded to prior treatment. The goal was to check safety and how well the drug works. Zanubrutinib is taken as a pill twice daily and targets a protein that …

This early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…

This study looked at whether giving the drug bortezomib after intensive chemotherapy, immunotherapy, and a stem cell transplant can help prevent mantle cell lymphoma from coming back. 151 patients were randomly assigned to receive bortezomib either as maintenance (long-term) or c…

This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…

This study tested a combination of ibrutinib and rituximab against other standard drug pairs in 36 people with mantle cell lymphoma that had returned or stopped responding to treatment. The main goal was to check safety and side effects, and to keep giving the treatment to those …

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…

This study examined whether PET scans can help doctors better stage mantle cell lymphoma and predict how patients will fare, compared to standard CT scans and bone marrow biopsies. Researchers analyzed data from 200 patients who had already completed a clinical trial. The goal wa…

This study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…

This study created a registry of 227 adults with mantle cell lymphoma who had recently started a new type of therapy. Researchers tracked which treatments were used, how long patients stayed on them, and how patients rated their own quality of life. The goal was to gather real-wo…

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…